Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 3.
FIG. 3.

Effect of GCCR ASO treatment on circulating lipids in ZDF and HFD-STZ rats. Rats were dosed with saline (□), GCCR ASO 37.5 mg/kg (▪), or control ASO 37.5 mg/kg ([cjs2112]) subcutaneously twice a week for 4 weeks. Blood samples were collected at the end of the study in the fed state, and lipids were analyzed as described in research design and methods. Data are expressed as means ± SE. *P < 0.05, GCCR ASO treatment vs. saline treatment.

This Article

  1. Diabetes vol. 54 no. 6 1846-1853